Abstract
We investigated whether 5-HT2A receptors contribute to the control of attentional performance by glutamate NMDA receptor mechanisms in the medial prefrontal cortex (mPFC). We examined the effects of NMDA receptor blockade in the mPFC on attentional performance by infusing a competitive glutamate NMDA receptor antagonist, 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP) into the mPFC of rats performing a task of divided and sustained visual attention. The five-choice serial reaction time task provides indices of attentional functioning (% correct responses), executive control (measured by anticipatory and perseverative responses) and speed. A dose of 10 ng CPP injected bilaterally into the mPFC increased anticipatory and perseverative responding; 50 ng reduced accuracy. Increasing the stimulus duration alleviated the CPP-induced accuracy deficit but did not reduce its effects on anticipatory and perseverative responses. CPP at 50 ng caused motor hyperactivity whereas lower doses had no effect. [R-(+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol] (M100907) (M100907), a 5-HT2A receptor antagonist, injected subcutaneously at 10 and 40 μg/kg, had no effect on accuracy but dose dependently reversed the impairment induced by 50 ng CPP. Both doses of M100907 completely abolished CPP-induced anticipatory but not perseverative over-responding. At the dose of 40 μg/kg M100907 reversed CPP-induced motor hyperactivity. This study provides evidence that the prefronto-cortical glutamate NMDA system may make an important contribution to the control of attention and executive functions. It also indicates that 5-HT2A receptors may serve to optimize attentional selectivity and improve some aspects of executive control.
Similar content being viewed by others
INTRODUCTION
The prefrontal cortex has been implicated in a variety of cognitive functions, including working memory, visual attention, and executive functions (Shallice, 1982; Fuster, 1989; Corbetta et al, 1991; Duncan, 1995, 2001; Baddeley, 1996; Goldman-Rakic, 1998; Robbins, 1998). Lesions of the medial prefrontal cortex (mPFC) but not the cingulate, anterior-lateral or parietal cortex in rats impair attentional functioning and cause compulsive perseveration in a task of sustained and divided attention (Muir et al, 1996; Passetti et al, 2002, 2003a, 2003b).
Cognitive deficits, including attention disorders and deficits in executive functions, are a central feature of schizophrenia (Frith, 1987; Kay and Sevy, 1990; Braff, 1993). Phencyclidine and ketamine, noncompetitive antagonists at glutamate NMDA receptors, exacerbate positive and negative symptoms in schizophrenic patients, and induce schizophrenia-like symptoms and cognitive deficits in healthy volunteers (Javitt and Zukin, 1991; Krystal et al, 1994). This is in line with findings in rodents that intracortical or peripheral administration of NMDA receptor antagonists causes deficits in sensory-motor gating (Jentsch and Roth, 1999), hyperactivity (O'Neill and Liebman, 1987; Jentsch et al, 1998), and working memory (Wesierska et al, 1990; Verma and Moghaddam, 1996; Moghaddam et al, 1997; Aura and Riekkinen, 1999; Romanides et al, 1999). Peripherally administered phencyclidine or dizocilpine, noncompetitive NMDA receptor antagonists, or the selective NMDA-R2B receptor antagonist Ro 63-1908, cause deficits in attentional performance in a five-choice serial reaction time (5-CSRT) task (Higgins et al, 2003; Le Pen et al, 2003).
Serotonin receptors are increasingly recognized as major targets for cognitive enhancement in schizophrenia (Meltzer et al, 2003; Roth et al, 2003). Indeed, all the currently available atypical antipsychotics such as clozapine, risperidone, olanzapine, quietapine, and ziprasidone, which are potent serotonin 5-HT2A receptor antagonists (Meltzer, 1999) consistently improve an aspect of attention such as vigilance and to some extent favor executive functions in patients with schizophrenia (Meltzer and McGurk, 1999; Harvey and Keefe, 2001; Harvey et al, 2003, 2004).
Serotonin 5-HT2A receptor subtypes are found in many regions of the CNS (Barnes and Sharp, 1999) and appear to be particularly rich in neo-cortical regions including layer V of the prefrontal cortex (Jakab and Goldman-Rakic, 1998, 2000). Serotonin, through 5-HT2A receptors, enhances glutamate-induced excitatory postsynaptic currents in the prefrontal cortex (Aghajanian and Marek, 1997). Stimulation of 5-HT2A receptors by [(±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI) activates the glutamatergic-thalamo-cortical neurons, as revealed by Fos induction (Scruggs et al, 2000), increases cortical glutamate efflux (Scruggs et al, 2003), and indirectly activates AMPA/kainate receptors (Martin-Ruiz et al, 2001). Administration of NMDA antagonists or knocking out NMDA receptor functions raises extracellular 5-HT efflux in the mPFC (Martin et al, 1998; Miyamoto et al, 2001).
Agonists at 5-HT2A receptors impair attentional functioning and inhibitory response control in rats (Carli and Samanin, 1992; Koskinen et al, 2000). In contrast, the selective 5-HT2A receptor antagonist [R-(+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol] (M100907) (Kehne et al, 1996) reduces Fos expression induced by NMDA receptor antagonists (Habara et al, 2001). M100907 also reduces the elevated locomotor activity (Gleason and Shannon, 1997; Martin et al, 1997), forced swim immobility (Corbett et al, 1999), and deficit in prepulse inhibition (Varty et al, 1999) induced by NMDA receptor antagonists. In rats performing a 5-CSRT task, M100907 improved attentional performance (Winstanley et al, 2003; Passetti et al, 2003a) and reversed the deficit in inhibitory response control induced by systemic administration of the NMDA receptor antagonists, dizocilpine and Ro 63-1908 (Higgins et al, 2004).
The present study investigated whether 5-HT2A receptors contribute to the control of attentional performance exerted by glutamate NMDA receptor mechanisms in the mPFC. Rats' attentional performance was assessed in a 5-CSRT task, which measures different types of performance that include aspects of attention (measured by accuracy of detection) and executive control such as impulsive (anticipatory) and compulsive (perseverative) responding and provides various measures of speed of responding and motivation (Robbins, 2002). Thus in the present study, we infused various doses of a competitive NMDA receptor antagonist, 3-(R)-2-carboxypiperazin-4-propyl-l-phosphonic acid (CPP) directly into the mPFC, which is particularly rich in NMDA receptors (Cotman and Iversen, 1987). We also examined the effects of CPP in conditions of decreased attentional load by introducing ‘challenge’ sessions with longer stimulus duration. The effect of CPP on motor activation was also assessed. We investigated the contribution of 5-HT2A receptors to CPP-induced impairment in attentional performance using M100907, a selective 5-HT2A receptor antagonist, which has 300 times more affinity for 5-HT2A receptors than other receptor subtypes including 5-HT2C and α-1 adrenergic receptors (Kehne et al, 1996). Various doses of M100907 were injected subcutaneously to rats, which were given microinjections of CPP into the mPFC. We also examined the effect of M100907 on motor activation induced by CPP.
MATERIALS AND METHODS
Animals
Twenty-seven male Lister Hooded rats (Charles River, Italy) weighing between 300 and 350 g before surgery were used to examine the effects of various treatments on the performance of a 5-CSRT task. They were housed in pairs until surgery and then singly in a temperature-controlled room (21°C) with a day/night cycle (07:00–19:00). Water was available ad libitum. Limited access to food (about 15 g/rat of Altromin pellets) at the end of each day's testing kept the animals at 85–90% of their initial free-feeding weight. The male Lister Hooded rats (n=64) (Charles River, Italy) used to assess the effects of treatments on motor activity had free access to food.
Procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with the national (D.L. n. 116, G.U., suppl., 40, 18 Febbraio 1992, Circolare No. 8, G.U., 14 luglio 1994) and international laws and policies (EEC Council Directive 86/609, OJ L 358,1, Dec. 12, 1987; Guide for the Care and Use of Laboratory Animals, US National Research Council, 1996).
Apparatus
The test apparatus has been described in detail previously (Carli et al, 1983). It consisted of two 25 × 25 cm aluminum chambers built in the Department of Experimental Psychology, University of Cambridge. The rear wall of each box was concavely curved, and had set into its full arc nine square holes, 4 cm deep and 2 cm above floor level. Each hole had an infrared beam crossing the entrance vertically and illuminating a photoelectric cell. A standard 3 W bulb at the rear of each hole provided illumination. Food pellets (Sandown Scientific, UK) were delivered to a tray at the front of the box. A hinged panel blocked the entrance to the tray. A 3 W house-light was installed centrally in the box roof. Each apparatus was controlled on-line and data were collected by a Control Universal Cube microcomputer system (Cambridge, UK), with software written in ONLIBASIC.
Behavioral Procedures
5-CSRT task
Animals were trained on the 5-CSRT task to a stable performance as previously described (Carli et al, 1983). The start of the session was signaled by illumination of the house-light and the delivery of a single food pellet. Opening the panel to collect the pellet began the first trial. After a fixed delay (the intertrial interval, ITI), the light at the rear of one of the holes came on for a short period. The light stimulus was presented in each hole for an equal number of times during the course of a complete session, with the order of presentation randomized by the computer. While the light was on, and for a short period afterwards (the limited hold), responses in the hole that was illuminated (correct response) resulted in the delivery of a food pellet. Responses in the holes that had not been illuminated (incorrect responses) or failure to respond within the limited hold (omissions) caused the houselights to be turned off for a short period (time out). Responses made in the holes while the house-light was off restarted the time out.
After the delivery of food, or at the end of time out, the rat started the next trial by opening the panel at the front of the chamber. Responses made in the holes after a correct response (perseverative responses), or after the end of time out before opening the panel, resulted in a period of time out. Responses made in the holes during the ITI (anticipatory responses) also resulted in a period of time out. After anticipatory responses, however, opening the panel restarted the current trial.
Each daily session consisted of 100 trials or 30 min of testing, whichever was completed sooner, after which all lights were turned off and further responses had no effect.
In the first session of the test schedule the stimulus and limited hold each lasted 1 min and, depending on individual performances, they were progressively reduced to 0.5 s. The ITI and time out both lasted 2 s during the first session and the ITI was raised to 5 s in subsequent sessions; time out was not changed. When the rats reached a stable performance with a mean of 80% correct responses and no more than 15% omissions, they were allocated to different treatment schedules. Each rat had only one session on the 5-CSRT task per day throughout the experiments.
Motor activity
Motor activity was assessed in activity cages (40 × 25 × 18 cm) equipped with infrared photocell beams running horizontally along the axis of the cage (6 cm from the cage-end and 1 cm above the floor). The apparatus was controlled and data were collected by an Acorn computer system equipped with SPIDER extension (Paul Fray, Cambridge, UK). Rats were implanted with cannulae in the mPFC. After 7 days of recovery the animals were habituated to the activity cages for 1 h after which they were taken out and after the appropriate treatment put back into the activity cage, and the photocell beam interruptions were recorded over a 2 h period in 5-min bins.
Surgery
Rats previously trained to a stable level of performance were anesthetized with Equithesin (9.7 mg/ml sodium pentobarbital in saline +42.6 mg/ml chloral hydrate in propylenglycol +21.2 mg/ml Mg2SO4 in ethanol; 3.0 ml/kg intraperitoneally, i.p.), and secured in a stereotaxic frame (Kopf Ins., USA) with the incisor bar set at −3.3 mm relative to the interaural line. Bilateral 23-gauge, stainless-steel guide cannulae (Cooper's Needles, UK) were implanted in the medial region of the prefrontal cortex using standard stereotaxic techniques and secured to the skull using three bone screws and dental cement. The co-ordinates used were: anterior–posterior +3.8 mm from bregma, lateral ±0.8 mm from midline, and dorsal–ventral −3.2 from dura (Paxinos and Watson, 1982). Thirty-gauge stainless-steel stylets flush with the end of the guide cannulae were inserted in the guide cannulae. After surgery rats were housed singly and had 1 week of recovery without training on the 5-CSRT task. After recovery all rats were retrained on the task to re-establish a presurgery level of baseline performance.
Micro-infusion procedure
On testing days, while the rat was held, the stylets were removed and two injection units terminating 2 mm below the tip of the guides were inserted. A volume of 1 μl per hemisphere of various doses of CPP or saline was delivered at a rate of 0.5 μl/min by a 10 μl Hamilton syringe mounted in a CMA/100 infusion pump (CMA Microdialysis, Sweden), connected by PP10 tubing to the injection units. Injection units were left in place for 1 min to allow for diffusion.
Histology
After completion of the behavioral testing, rats were killed by a lethal dose of Equithesin and perfused transcardially with phosphate buffer saline followed by 4% formalin solution. Brains were removed and postfixed in 4% formalin solution. Before being cut, the brains were transferred to 20% sucrose in 0.2 M phosphate buffer saline. Coronal sections were cut at 30 μm in a Cryo-cut and stained with cresyl violet. Inspection of the stained slides under the light microscope and the trajectory of gliosis produced by the cannula allowed its location and tip to be estimated and mapped on figures of the atlas (Paxinos and Watson, 1982) (Figure 1). Only data from rats in which the cannulae were located in the desired area were included in the results. Three rats were excluded because of infection at the injection site.
Drugs and experimental design
CPP (Tocris, UK) was dissolved in 1 μl saline and injected into the mPFC at various doses 10 min before the test session. M100907 (Aventis, USA) was dissolved in 2 ml vehicle (sterile water with two to three drops of 90% lactic acid). Vehicle or M100907 was given subcutaneously 20 min before a microinjection of 1 μl saline or 50 ng/μl CPP into the mPFC.
Each rat used in the CPP dose–response study (n=9) received saline (1 μl) or 1, 10, and 50 ng/μl CPP. To examine the effects of CPP in conditions of increased stimulus duration, each rat (n=9) received 1 μl saline or 50 ng/μl CPP injected into the mPFC and was exposed to sessions in which stimulus duration was 0.5 or 1.0 s. A similar experimental design was used to examine the effects of various combinations of vehicle (2 ml/kg) and 10 or 40 μg/kg M100907 plus 1 μl saline or 50 ng/μl CPP injected into the mPFC (n=9). We also examined the effects of vehicle (2 ml/kg) or 10 and 40 μg/kg M100907 during ‘challenge’ sessions in which the ITI was increased from the standard 5 to 7 s.
On each test day drugs or the various combinations were administered according to a Latin-square design. At least 2 days were left between test days. Rats were always tested on these ‘free’ days to re-establish the baseline and check the lasting effects of drugs.
The effects of various doses of CPP on motor activity were assessed using 24 experimentally naïve rats implanted with cannulae in the mPFC. After habituation to the activity cages rats were injected with 1, 10, and 50 ng/μl CPP or 1 μl vehicle and 10 min later were placed in the activity cages. The interaction between M100907 and CPP on motor activity was assessed in a group of 40 rats implanted with cannulae in the mPFC. After habituation to the activity cages the rats were injected subcutaneously with vehicle (2 ml/kg) or M100907 (10 and 40 μg/kg) and 20 min later received bilateral injections of CPP (50 ng/μl) or vehicle (1 μl) into the mPFC. After 10 min, they were transferred to the activity cages and their motor activity was recorded. The effects of CPP on motor activity decayed rapidly and after the first 30 min the effects were extremely variable. Thus, only the data collected during the first 30 min of testing were statistically analyzed and are presented in the Results section.
Statistical analysis
The main dependent variables selected for analysis were: (a) the percentage of correct responses (total correct responses/total correct+total incorrect responses × 100); (b) percentage of omissions (total omissions/total number of trials × 100); (c) mean correct response latency (measured to the nearest 0.01 s); (d) the number of anticipatory responses in the holes during the ITI; and (e) the number of perseverative responses in the holes after a correct response.
We also measured and analyzed the mean latency to make an incorrect response, mean latency to collect the earned food pellet (both measured to the nearest 0.01 s) and the number of panel-pushes during ITI. However, CPP, M100907 or their combinations had no effect on these measures and they are not presented or discussed.
Correct responses and omissions, as percentages, were transformed according to the formula 2 arcsin(SQRT (%X/100)). The mean latencies to respond correctly were transformed by log 10. These transformations were done in order to normalize the distributions in accordance with the ANOVA model (Winer, 1971).
The CPP dose–response results and the effects of M100907 in conditions of increased ITI were analyzed by within-subjects one-way ANOVA, and the means of individual treatments were compared with saline by Dunnett's t-test. The results of the experiments testing the effects of 50 ng/μl CPP in combination with different stimulus durations (0.5 and 1.0 s) or different doses of M100907 (10 and 40 μg/kg) were analyzed by within-subjects two-way ANOVA. The means of the individual treatment combinations were compared by Tukey's HDS test.
The motor activity data recorded in 5-min time bins were summed over the first 30 min of the test period and analyzed by between-subjects one-way or two-way ANOVA, as appropriate. The means of individual treatments were compared with controls using Dunnett's t-test. Tukey's HDS test was employed for multiple comparisons of the means for various individual treatments.
Statistical software (SAS Institute Inc., USA) was run on a Micro VAX 3500 computer (Digital, USA).
RESULTS
The gray areas in Figure 1 depict the location of the injector tips of rats included in the results. The majority was confined to the prelimbic area between bregma +4.2 and +3.7. In some rats the tips were between bregma +3.7 and +3.2. However, we did not observe any difference in the behavioral results of rats with injection tips confined to the more anterior (bregma 4.2–3.7) or the posterior (bregma 3.7–3.2) area of mPFC. Repeated injections did not cause extensive damage and only a few animals had signs of infection so were not included in the results.
Effects of CPP on Performance of a 5-CSRT Task
Baseline condition
Figure 2a shows how CPP impaired rats' discriminative accuracy. Overall, CPP (1, 10, and 50 ng/μl per side) dose dependently lowered the percentage of correct responses (F(3,21)=6.4, P=0.003). However, despite the apparent decrease with 10 ng/μl (P>0.05, Tukey's test), the percentage was only significantly lower after 50 ng/μl (P<0.05, Tukey's test). In parallel to the deleterious effects on accuracy, Table 1 shows that CPP increased omissions (F(3,21)=10.59, P=0.0002) and correct response latencies (F(3,21)=5.6, P=0.005). The omissions were significantly increased by 50 ng/μl (P<0.05, Tukey's test) while both 10 and 50 ng/μl increased correct response latencies (both P<0.05, Tukey's test).
In addition, CPP particularly impaired the rats' ability to withhold inappropriate nose-poke responses, as shown by increased number of anticipatory (F(3,21)=5.3, P=0.007) (Figure 2b) and perseverative responses (F(3,21)=3.95, P=0.02) (Figure 2c). These increases were already maximal at 10 ng/μl and did not rise further with 50 ng/μl (both Tukey's test P<0.05). The dose of 1 ng/μl had no effect on any measure of attentional performance.
Increased stimulus duration
The performance accuracy and omissions are shown in Figure 3a and Table 2, respectively. The deficits of rats injected with 50 ng/μl CPP were abolished when the stimulus duration was increased to 1.0 s from the standard 0.5 s (% correct responses: stimulus × CPP, F(1,24)=6.7, P=0.016; CPP, F(1,24)=12.2, P=0.002; stimulus, F(1,24)=32.1, P=0.0001; % omissions: stimulus × CPP, F(1,24)=6.8, P=0.01; CPP, F(1,24)=9.46, P=0.005; stimulus, F(1,24)=1.3, P>0.05). Table 2 shows that the longer stimulus, or CPP injections in rats performing at the 0.5 s stimulus increased correct response latencies. However, these effects were not additive. CPP did not increase correct response latency when the rats performed the task with the 1.0 s stimulus (stimulus × CPP, F(1,24)=6.9, P=0.01; CPP, F(1,24)=10.1, P=0.004; stimulus, F(1,24)=1.5, P>0.05) (Table 2).
Increasing the stimulus duration reduced the number of anticipatory (Figure 3b) and perseverative (Figure 3c) responses in controls and CPP-treated rats (F(1,24)=4.2, P=0.05; F(1,24)=17.5, P=0.002; respectively). These nose-pokes were increased proportionally by CPP at both stimulus durations (anticipatory; stimulus × CPP, F(1,24)=1.5, P>0.05; CPP, F(1,24)=22.7, P=0.0001 and perseverative; stimulus × CPP, F(1,24)=0.8, P>0.05; CPP, F(1,24)=27.7, P=0.0003).
Effects of M100907 on CPP-Induced Impairments in Attentional Performance
Figure 4a shows how the effects of 50 ng/μl CPP in the mPFC on accuracy were modified by the selective 5-HT2A receptor antagonist, M100907 administered subcutaneously. Doses of 10 and 40 μg/kg M100907 by themselves had no effect on accuracy but dose dependently prevented the effects of CPP on the percentage of correct responses (M100907 × CPP, F(2,40)=6.1, P=0.005; M100907, F(2,40)=2.9, P=0.07; CPP, F(1,40)=13.5, P=0.0007). M100907 10 μg/kg significantly reduced (P<0.05; Tukey's test) and 40 μg/kg completely abolished the accuracy impairment induced by CPP (P<0.05 Tukey's test). As shown in Table 3, the combination of CPP plus 40 μg/kg M100907 had additive effects on omissions (M100907 × CPP, F(2,40)=0.87, P>0.05; M100907, F(2,40)=6.4, P=0.004; CPP, F(1,40)=43.0, P=0.0001) and correct response latency (M100907 × CPP, F(2,40)=0.5, P>0.05; M100907, F(2,40)=9.8, P=0.0003; CPP, F(1,40)=25.7 P=0.0001).
The CPP-induced increase in anticipatory responses (Figure 4b) was completely abolished by 10 and 40 μg/kg of M100907 (M100907 × CPP, F(2,40)=6.8, P=0.003; M100907, F(2,40)=11.4, P=0.0001; CPP, F(1,40)=27.8, P=0.0001). M100907 alone tended to reduce anticipatory responses, but not significantly probably, because the number of anticipatory responses in the control condition was already low. Increasing the ITI from 5 to 7 s resulted in an overall increase in anticipatory responses (ITI 5 s, vehicle=3.3±1.4; ITI 7 s, vehicle=31.5±5.2; P<0.05 Student's t-test). Anticipatory responses significantly decreased with M100907 (F(2,10)=15.1, P<0.001), from 31.5±5.2 (vehicle) to 11.8±2.6 (10 μg/kg) and 5.8±1.2 (40 μg/kg). Figure 4c shows that M100907 by itself reduced the number of perseverative responses (both doses, P<0.05, Tukey's test) but did not affect CPP-induced perseverative over-responding (M100907 × CPP, F(2,40)=0.06, P>0.05; M100907, F(2,40)=0.8, P=0.47; CPP, F(1,40)=17.3, P=0.0002).
Motor activity
Motor activity was increased with CPP (vehicle 127±17 (n=6); CPP 1 ng/μl 122±17 (n=6); CPP 10 ng/μl 137±31 (n=6); CPP 50 ng/μl 205±32 (n=6)). Table 4 presents the effects of M100907 on CPP-induced motor hyperactivity. A two-way ANOVA on activity counts showed that 50 ng/μl of CPP injected into the mPFC significantly increased motor activity, as indicated by the significant main effect of CPP (F(1,34)=17.0, P=0.0002). The main effect of M100907 was also significant (F(2,34)=11.9, P=0.0001). Post hoc analysis showed that both doses of M100907 reduced the motor activity of control rats (Tukey's test, P<0.05). The interaction between M100907 pretreatment and CPP was not significant (F(2,34)=2.4, P=0.10). However, post hoc tests comparing the means of various individual treatments indicated that M100907 40 μg/kg significantly reduced the effects of CPP on motor activity (Tukey's test, P<0.05).
DISCUSSION
This study found a functional interaction between serotonin 5-HT2A receptor mechanisms and medial prefronto-cortical NMDA receptors in the control of attentional performance. The selective and competitive glutamate NMDA receptor antagonist CPP (Lehmann et al, 1987), injected into the mPFC, had profound effects on rats' attentional performance. At 10 ng/μl it enhanced anticipatory and perseverative responding and increased the correct response latencies while 50 ng/μl impaired accuracy and omissions. M100907, a selective 5-HT2A receptor antagonist (Kehne et al, 1996), injected subcutaneously at 10 and 40 μg/kg, had no effect on accuracy but dose dependently prevented the impairment induced by 50 ng/μl CPP. The dose of 10 μg/kg M100907 already completely abolished CPP-induced anticipatory responding but perseverative over-responding was not affected by any dose. Both doses of M100907 decreased motor activity whereas 40 but not 10 μg/kg M100907 reversed CPP-induced motor hyperactivity.
The severe deficit in accuracy accompanied by the increases in omissions and latencies for correct detection indicate that CPP caused a pronounced attentional performance deficit. Similar deficits in accuracy, omissions, and correct response latencies in a 5-CSRT task have been reported after systemically administered noncompetitive NMDA receptor antagonists, dizocilpine, and phencyclidine (Higgins et al, 2003; Le Pen et al, 2003) and lesions of the mPFC (Muir et al, 1996; Passetti et al, 2002). At the dose that impaired accuracy of detection CPP injected into the mPFC increased motor activity. However, it is difficult to explain the accuracy impairment as a simple motor effect since correct and incorrect responses in this task have the same motor requirements. In addition, the accuracy deficit induced by the high dose of CPP was completely abolished when the attentional load on performance was reduced, by prolonging the stimulus. Omissions, which occur when the subject does not orient its attention on the stimulus presentation array in time might reflect motor or motivational factors. Again, prolonging the stimulus abolished CPP-induced increases in omissions. Therefore, these findings rule out the possibility that the CPP-induced impairment in accuracy was a consequence of hyperactivity, poor motivation or a failure to make associations or remember the general rules of the task.
Despite the profound impairment in attentional performance induced by blockade of NMDA receptors in the mPFC, the selective and potent 5-HT2A antagonist M100907 administered systemically dose dependently reversed the accuracy impairment induced by CPP. Systemic M100907 alone had no effect on accuracy in a 5-CSRT task (present result; Higgins et al, 2004; Winstanley et al, 2003) whereas when injected into the mPFC it boasted accuracy (Winstanley et al, 2003). This may be due to opposite effects of prefronto-cortical and subcortical 5-HT2A receptor blockade when the drug is administered by a systemic route. Previous work has shown that 5-HT lesion of the dorsal raphe (DR) nucleus improves attentional functioning (Harrison et al, 1997b). This 5-HT depletion, restricted to certain forebrain areas such as the cortex and striatum, presumably lowers 5-HT neurotransmission at all 5-HT receptor subtypes along the fronto-cortico-striatal loop but, as shown by Winstanley et al (2003), blockade of 5-HT2A receptors in the mPFC has effects similar to 5-HT lesions of the DR nucleus. On the other hand, stimulation of 5-HT2A receptors by DOI had no effect on accuracy (Koskinen et al, 2000). These findings suggest that serotonin, through 5-HT2A receptors, exerts a tonic control on attentional functioning, so reducing serotonergic function at 5-HT2A receptors might help preserve the attentional selectivity.
M100907 added its effects on the rate of omissions and correct response latencies to those of CPP, suggestive of some effects on motivation or motor activity. However, combined treatment did not cause a general disruption of performance and the majority of rats completed 100 trials within the allotted time (30 min). Although M100907 by itself reduced motor activity, thus supporting the interpretation that the increase in omissions and response latency might reflect some motor factors, it completely abolished CPP-induced hyperactivity. As a whole, these data again suggest that the effects of M100907 and CPP on omissions and correct response latency cannot be explained in terms of a simple change in motor activity.
CPP caused considerable impairment in executive control of the task, at 10 ng/μl a dose that did not affect motor activity or accuracy of detection. The failure in executive functions, as exemplified by the CPP-induced increase in anticipatory and perseverative responses, persisted even when the longer stimulus helped alleviate the accuracy deficit. This suggests that the deficits in anticipatory and perseverative responses were relatively independent from processes involving stimulus detection or motor activation. An almost identical effect on anticipatory and perseverative responses was observed after systemic administration of NMDA antagonists (Higgins et al, 2003; Le Pen et al, 2003).
That the effects of CPP on attentional functioning may be dissociated from its effects on inhibitory response control is further suggested by the fact that 10 μg/kg M100907, a dose that only partially counteracted CPP' effects on accuracy, completely abolished the CPP-induced increase in anticipatory responses. Although in our study M100907 tended to reduce the anticipatory responses of rats performing under control conditions, the effect was not statistically significant, probably because of the small number of anticipatory responses by controls. However, we found that 10 and 40 μg/kg M100907 significantly reduced anticipatory responding when the ITI was increased from 5 to 7 s, thus allowing more anticipatory responses.
The effects of M100907 on CPP-induced anticipatory over-responding are similar to those reported recently by Higgins et al (2004) showing that M100907, although at doses 10 times those used in the present study, reversed the effects of the noncompetitive NMDA receptor antagonist dizocilpine and an NR2B-selective NMDA receptor antagonist Ro 63-1908 on anticipatory responding in a 5-CSRT task. It is interesting that the NMDA antagonists increased the release of 5-HT in the mPFC (Martin et al, 1998) and that poor inhibitory response control in a 5-CSRT task, measured by anticipatory responses, was associated with high 5-HT turnover (Puumala and Sirvio, 1998) or release in the mPFC (Dalley et al, 2002). Consistent with these findings is that stimulation of 5-HT2A receptors by a variety of nonselective 5-HT2A agonists increased while 5-HT2A receptor antagonists reduced anticipatory responses (Carli and Samanin, 1992; Ruotsalainen et al, 1997; Koskinen et al, 2000; Koskinen and Sirvio, 2001; Winstanley et al, 2003; Passetti et al, 2003a).
Therefore, over-activation of 5-HT2A receptors in the mPFC as a consequence of elevated 5-HT release in this cortical area may be an important mechanism that increases active responding in anticipation of reward. However, these findings challenge the view that loss of response control is necessarily mediated by diminished 5-HT function, since global forebrain 5-HT depletion consistently results in enhanced impulsivity in the rat (Harrison et al, 1997a). This apparent discrepancy may be explained by 5-HT exerting tonic inhibition on impulsivity through 5-HT2C receptors since blocking them greatly increased anticipatory responding in a 5-CSRT task (Higgins et al, 2004). Thus 5-HT, probably through opposite action on 5-HT2A and 5-HT2C receptors, contributes to the mechanisms responsible for preventing the disruptive consequences of loss of inhibitory response control on attentional performance.
Previous studies have strongly implicated the anterior cingulate cortex in the control of anticipatory responses (Muir et al, 1996). However, it is unlikely that diffusion of CPP into the anterior cingulate cortex contributed in some major way to the increased anticipatory responding. Doses of CPP (10 and 50 ng/μl) similar to those used in the present study had to be injected into the anterior cingulate cortex to induce anticipatory over-responding (M Carli and M Baviera, unpublished observation).
The increased perseveration, which is in line with that reported after excitotoxic lesions of the mPFC (Muir et al, 1996) could be the result of CPP preventing the suppression of responses once effective for obtaining reward. The enhanced tendency to perseverate appears to be a distinctive trait of frontal-lesion animals (Mishkin, 1964; Muir et al, 1996; Dias et al, 1997; Ragozzino et al, 1999; Killcross and Coutureau, 2003), and of frontal-lobe patients when required to inhibit previously reinforced responses (Owen et al, 1993). In addition, schizophrenic patients show increased perseverative responding in a two-choice visual task (Lyon and Gerlach, 1988) and in the Wisconsin Card Sorting Test, a task sensitive to prefronto-cortical dysfunction (Goldberg and Weinberger, 1994).
It is interesting that M100907 did not prevent the compulsive perseveration induced by CPP. This implies that the mechanisms of executive control impaired in perseveration may be different from those involved in anticipatory responding. Clearly, this double dissociation indicates that the two inhibitory processes can be differentiated at the level of the 5-HT2A receptor mechanisms.
Hyperactivity elicited by CPP injected into the mPFC was reduced by M100907 at the dose of 40 μg/kg. This dose is similar to the ED50 of 30 μg/kg reported to block dizocilpine-induced hyperactivity in rats (Higgins et al, 2004). However, in contrast to published results we found that M100907 reduced spontaneous motor activity at doses 300 times lower than those previously reported in mice (Martin et al, 1997).
Behavioral deficits induced by acutely administered NMDA antagonists have been associated with enhanced glutamate release in the mPFC (Moghaddam et al, 1997; Moghaddam and Adams, 1998). Preliminary findings in our laboratory indicate that CPP in the mPFC increases glutamate efflux locally and this was prevented by systemic M100907 at doses similar to those used in the present study (Invernizzi et al, 2003). Therefore, it is likely that the suppression of glutamate release contributed to the mechanism by which M100907 prevents the effects of CPP on attentional performance. It would be of interest to study the effects of 5-HT2A blockade under other conditions that may alter cortical functions and impair attentional performance, such as selective cholinergic lesions of the nucleus basalis magnocellularis which complement those of CPP in the mPFC, thus providing further insights into the functional significance of the blockade of 5-HT2A receptors.
The failure in functions concerned with allocation of attentional resources (Shallice, 1982) is generally considered a mark of frontal lobe dysfunction (Owen et al, 1993) and attentional impairments and cognitive rigidity are well-known features of schizophrenia (Shallice et al, 1991; Elliott et al, 1998). Cognitive functions of the prefrontal cortex are modulated by an optimal level of mesocortical dopamine (DA) function (Arnsten, 1997; Zahrt et al, 1997). Attentional performance may be affected by fluctuations in prefrontal DA functions (Roberts et al, 1994; Granon et al, 2000). Thus, the increase in DA release in the mPFC as opposed to other brain areas such as the nucleus accumbens induced by some 5-HT2A antagonists, or their ability to enhance the effects of DA D2 antagonists such as haloperidol on DA release in the mPFC (Bonaccorso et al, 2002; Liegeois et al, 2002) may be relevant to how atypical antipsychotics improve cognitive functions. The facilitation of attentional performance revealed by the present data also help explain why atypical antipsychotics such as clozapine, risperidone, olanzapine, quietiapine, and ziprasidone—all potent 5-HT2A antagonists—have beneficial effects on attention and executive functions in schizophrenic patients (Harvey and Keefe, 2001; Harvey et al, 2003, 2004), beyond those of the typical antipsychotic drugs (Honey et al, 1999; Meltzer and McGurk, 1999).
Although it is problematic to extrapolate data from animal studies to complex human diseases such as schizophrenia, these results are compatible with the notion that dysfunctional glutamate NMDA neurotransmission within the PFC, and hyperfunction of 5-HT neuronal systems, are implicated in the pathophysiology of schizophrenia (Seeman et al, 1976; Javitt and Zukin, 1991; Meltzer, 1991; Tsai and Coyle, 2002).
The present study provides evidence that the prefronto-cortical glutamatergic–NMDA system may make an important contribution to the control of attention and executive functions. It also shows that some aspects of executive functions such as inhibitory response control and compulsive repetition of responding may be differentiated at the level of 5-HT2A receptor function. Therefore, it could be concluded that 5-HT2A receptor function is relevant to processes that permit appropriate response selection and attentional selectivity in the face of interference induced by dysfunctional glutamate transmission in the prefrontal cortex.
References
Aghajanian GK, Marek GJ (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36: 589–599.
Arnsten AF (1997). Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11: 151–162.
Aura J, Riekkinen Jr P (1999). Blockade of NMDA receptors located at the dorsomedial prefrontal cortex impairs spatial working memory in rats. Neuroreport 10: 243–248.
Baddeley AD (1996). Exploring the central executive. Q J Exp Psychol 49A: 5–28.
Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083–1152.
Bonaccorso S, Meltzer HY, Li Z, Dai J, Alboszta AR, Ichikawa J (2002). SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 27: 430–441.
Braff DL (1993). Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 19: 233–259.
Carli M, Robbins TW, Evenden JL, Everitt BJ (1983). Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 9: 361–380.
Carli M, Samanin R (1992). Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task. Psychopharmacology 106: 228–234.
Corbett R, Zhou L, Sorensen SM, Mondadori C (1999). Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology 21: S211–S218.
Corbetta M, Miezin FM, Dobmeyer S, Shulman GL, Petersen SE (1991). Selective and divided attention during visual discriminations of shape, color, and speed: functional anatomy by positron emission tomography. J Neurosci 11: 2383–2402.
Cotman CW, Iversen LL (1987). Excitatory amino acids in the brain—focus on NMDA receptors. Trends Neurosci 10: 263–265.
Dalley JW, Theobald DE, Eagle DM, Passetti F, Robbins TW (2002). Deficits in impulse control associated with tonically-elevated serotonergic function in rat prefrontal cortex. Neuropsychopharmacology 26: 716–728.
Dias R, Robbins TW, Roberts AC (1997). Dissociable forms of inhibitory control within prefrontal cortex with an analog of the Wisconsin Card Sort Test: restriction to novel situations and independence from ‘on-line’ processing. J Neurosci 17: 9285–9297.
Duncan J (1995). Attention, intelligence and the frontal lobes. In: Gazzaniga MS (ed). The Cognitive Neurosciences. MIT Press: Cambridge, MA. pp 721–733.
Duncan J (2001). Frontal lobe function and the control of visual attention. In: Braun J, Koch C, Davis JL (ed). Visual Attention and Cortical Circuits. A Bradford Book, MIT Press: Cambridge, MA.
Elliott R, McKenna PJ, Robbins TW, Sahakian BJ (1998). Specific neuropsychological deficits in schizophrenic patients with preserved intellectual function. Cognitive Neuropsychiatry 3: 45–69.
Frith CD (1987). The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med 17: 631–648.
Fuster JM (1989). The Prefrontal Cortex, 2nd edn. Raven Press: New York.
Gleason SD, Shannon HE (1997). Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129: 79–84.
Goldberg TE, Weinberger DR (1994). Schizophrenia, training paradigms, and the Wisconsin Card Sorting Test redux. Schizophr Res 11: 291–296.
Goldman-Rakic PS (1998). The prefrontal landscape: implications of functional architecture for understanding human mentation and central executive. In: Robberts AC, Robbins TW, Weiskrantz L (eds). The Prefrontal Cortex. Executive and Cognitive Functions. Oxford University Press: Oxford.
Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW (2000). Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 20: 1208–1215.
Habara T, Hamamura T, Miki M, Ohashi K, Kuroda S (2001). M100907, a selective 5-HT(2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain. Eur J Pharmacol 417: 189–194.
Harrison AA, Everitt BJ, Robbins TW (1997a). Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl) 133: 329–342.
Harrison AA, Everitt BJ, Robbins TW (1997b). Doubly dissociable effects of median- and dorsal-raphe lesions on the performance of the five-choice serial reaction time test of attention in rats. Behav Brain Res 89: 135–149.
Harvey PD, Green MF, McGurk SR, Meltzer HY (2003). Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169: 404–411.
Harvey PD, Keefe RS (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158: 176–184.
Harvey PD, Siu CO, Romano S (2004). Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 172: 324–332.
Higgins GA, Ballard TM, Huwyler J, Kemp JA, Gill R (2003). Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology 44: 324–341.
Higgins GA, Enderlin M, Haman M, Fletcher PJ (2004). The 5-HT(2A) receptor antagonist M100,907 attenuates motor and ‘impulsive-type’ behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berl) 170: 309–319.
Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T (1999). Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 96: 13432–13437.
Invernizzi RW, Carli M, Baviera M, Ceglia I (2003). The 5-HT2A receptor antagonist M100907 prevents the increase of cortical extracellular glutamate induced by the local infusion of the NMDA receptor antagonist CPP. In: Svensson TH (ed). Monitoring Molecules in Neuroscience. Karolinska University Press: Stockholm, Sweden; Karolinska Instituten: Stockholm, Sweden. pp 79–81.
Jakab RL, Goldman-Rakic PS (1998). 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95: 735–740.
Jakab RL, Goldman-Rakic PS (2000). Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 417: 337–348.
Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301–1308.
Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201–225.
Jentsch JD, Tran A, Taylor JR, Roth RH (1998). Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology (Berl) 138: 89–95.
Kay SR, Sevy S (1990). Pyramidical model of schizophrenia. Schizophr Bull 16: 537–545.
Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ et al (1996). Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968–981.
Killcross S, Coutureau E (2003). Coordination of actions and habits in the medial prefrontal cortex of rats. Cereb Cortex 13: 400–408.
Koskinen T, Ruotsalainen S, Puumala T, Lappalainen R, Koivisto E, Mannisto PT et al (2000). Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task. Neuropharmacology 39: 471–481.
Koskinen T, Sirvio J (2001). Studies on the involvement of the dopaminergic system in the 5-HT2 agonist (DOI)-induced premature responding in a five-choice serial reaction time task. Brain Res Bull 54: 65–75.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199–214.
Le Pen G, Grottick AJ, Higgins GA, Moreau JL (2003). Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia. Neuropsychopharmacology 28: 1799–1809.
Lehmann J, Schneider J, McPherson S, Murphy DE, Bernard P, Tsai C et al (1987). CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo. J Pharmacol Exp Ther 240: 737–746.
Liegeois JF, Ichikawa J, Meltzer HY (2002). 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947: 157–165.
Lyon N, Gerlach J (1988). Perseverative structuring of responses by schizophrenic and affective disorder patients. J Psychiatr Res 22: 261–277.
Martin P, Carlsson ML, Hjorth S (1998). Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 9: 2985–2988.
Martin P, Waters N, Waters S, Carlsson A, Carlsson ML (1997). MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol 335: 107–116.
Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G et al (2001). Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21: 9856–9866.
Meltzer HY (1991). The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287.
Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21: 106S–115S.
Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159–1172.
Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233–255.
Mishkin M (1964). Perseveration of central sets after frontal lesions in monkeys. In: Akert K (ed). The Frontal Granular Cortex and Behaviour. McGraw-Hill: New York.
Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T (2001). Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci 21: 750–757.
Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349–1352.
Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921–2927.
Muir JL, Everitt BJ, Robbins TW (1996). The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task. Cereb Cortex 6: 470–481.
O'Neill KA, Liebman JM (1987). Unique behavioral effects of the NMDA antagonist, CPP, upon injection into the medial pre-frontal cortex of rats. Brain Res 435: 371–376.
Owen AM, Roberts AC, Hodges JR, Summers BA, Polkey CE, Robbins TW (1993). Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain 116: 1159–1175.
Passetti F, Chudasama Y, Robbins TW (2002). The frontal cortex of the rat and visual attentional performance: dissociable functions of distinct medial prefrontal subregions. Cereb Cortex 12: 1254–1268.
Passetti F, Dalley JW, Robbins TW (2003a). Double dissociation of serotonergic and dopaminergic mechanisms on attentional performance using a rodent five-choice reaction time task. Psychopharmacology (Berl) 165: 136–145.
Passetti F, Levita L, Robbins TW (2003b). Sulpiride alleviates the attentional impairments of rats with medial prefrontal cortex lesions. Behav Brain Res 138: 59–69.
Paxinos G, Watson C (1982). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney.
Puumala T, Sirvio J (1998). Changes in activities of dopamine and serotonin systems in the frontal cortex underlie poor choice accuracy and impulsivity of rats in an attention task. Neuroscience 83: 489–499.
Ragozzino ME, Detrick S, Kesner RP (1999). Involvement of the prelimbic-infralimbic areas of the rodent prefrontal cortex in behavioral flexibility for place and response learning. J Neurosci 19: 4585–4594.
Robbins TW (1998). Dissociating executive functions of the prefrontal cortex. In: Roberts AC, Robbins TW, Weiskrantz L (eds). The prefrontal Cortex: Executive and Cognitive Functions. Oxford University Press: Oxford, New York. pp 117–130.
Robbins TW (2002). The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163: 362–380.
Roberts AC, De Salvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ et al (1994). 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 14: 2531–2544.
Romanides AJ, Duffy P, Kalivas PW (1999). Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience 92: 97–106.
Roth BL, Hanizavareh SM, Blum AE (2003). Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl), Epub ahead of print.
Ruotsalainen S, Sirvio J, Jakala P, Puumala T, MacDonald E, Riekkinen Sr P (1997). Differential effects of three 5-HT receptor antagonists on the performance of rats in attentional and working memory tasks. Eur Neuropsychopharmacol 7: 99–108.
Scruggs JL, Patel S, Bubser M, Deutch AY (2000). DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci 20: 8846–8852.
Scruggs JL, Schmidt D, Deutch AY (2003). The hallucinogen 1--2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci Lett 346: 137–140.
Seeman P, Lee T, Chau-Wong M, Wong K (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717–719.
Shallice T (1982). Specific impairments of planning. Philos Trans R Soc Lond B: Biol Sci 298: 199–209.
Shallice T, Burgess PW, Frith CD (1991). Can the neuropsychological case-study approach be applied to schizophrenia? Psychol Med 21: 661–673.
Tsai G, Coyle JT (2002). Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42: 165–179.
Varty GB, Bakshi VP, Geyer MA (1999). M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague–Dawley and Wistar rats. Neuropsychopharmacology 20: 311–321.
Verma A, Moghaddam B (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373–379.
Wesierska M, Macias-Gonzalez R, Bures J (1990). Differential effect of ketamine on the reference and working memory versions of the Morris water maze task. Behav Neurosci 104: 74–83.
Winer BJ (1971). Statistical Principles in Experimental Design, 2nd edn. McGraw-Hill: Tokyo.
Winstanley CA, Chudasama Y, Dalley JW, Theobald DE, Glennon JC, Robbins TW (2003). Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl) 167: 304–314.
Zahrt J, Taylor JR, Mathew RG, Arnsten AF (1997). Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17: 8528–8535.
Acknowledgements
We thank Prof. Trevor W Robbins and Dr Gianluigi Forloni for their helpful discussion of these studies, Dr John L Evenden for his comments on the paper and Dr S Kongsamut (Aventis Pharmaceutical, USA) for the generous gift of M100907. Funding for these studies was provided by the Italian Ministry for University and Research (MIUR) grant RBAU01ZS5C.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mirjana, C., Baviera, M., Invernizzi, R. et al. The Serotonin 5-HT2A Receptors Antagonist M100907 Prevents Impairment in Attentional Performance by NMDA Receptor Blockade in the Rat Prefrontal Cortex. Neuropsychopharmacol 29, 1637–1647 (2004). https://doi.org/10.1038/sj.npp.1300479
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.npp.1300479
- Springer Nature Switzerland AG
Keywords
This article is cited by
-
Differences in trait impulsivity do not bias the response to pharmacological drug challenge in the rat five-choice serial reaction time task
Psychopharmacology (2018)
-
Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice
Psychopharmacology (2015)
-
Dissociable effects of mGluR5 allosteric modulation on distinct forms of impulsivity in rats: interaction with NMDA receptor antagonism
Psychopharmacology (2015)
-
Subanesthetic Ketamine Treatment Promotes Abnormal Interactions between Neural Subsystems and Alters the Properties of Functional Brain Networks
Neuropsychopharmacology (2014)
-
Dopamine D1-Like and D2-Like Receptors in the Dorsal Striatum Control Different Aspects of Attentional Performance in the Five-Choice Serial Reaction Time Task Under a Condition of Increased Activity of Corticostriatal Inputs
Neuropsychopharmacology (2013)